| Adenoviral oncoprotein E1B55K mediates colocalization of SSBP2 and PML in response to stress. | None |
| Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. | None |
| A high-content screening (HCS) assay for the identification of chemical inducers of PML oncogenic domains (PODs). | None |
| The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. | None |
| Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. | None |
| Coimmunoprecipitation assays showed that adenoviral oncogene E1A-13S preferentially interacts with only one (PML-II) of at least six nuclear human PML isoforms. | None |
| The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription. | None |
| The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. | None |
| The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. | None |
| Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. | None |
| Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. | None |